7 AI Stocks to Buy Revolutionizing Healthcare
Published: 2024-06-14
Status:
Analyzed
Published: 2024-06-14
Status:
Analyzed
Predictions from this Video
Incorrect: 0
Prediction
Topic
Status
Nvidia's stock returns over the next two years will not match the 700% returns seen in the prior two years, as it would require the company to reach a $24 trillion market cap.
"you are not going to see that same adex return you've seen over the last 2 years for that to happen Nvidia would have to grow to a $24 trillion company"
Pending
Intuitive Surgical (ISRG) is forecasted to achieve 13% revenue growth in 2024, 16% in 2025, and a 14% annual earnings growth.
"The company can count on forecasted Revenue growth of 13% this year and 16% next is expected to produce a 14% annual pace of earnings growth"
Pending
Vicarious Surgical (RBOT) is not expected to have its first clinical patient until 2025 and meaningful revenues for years after that.
"this is still a pre-revenue company with its first clinical patient not expected until next year and years outside meaningful revenues"
Pending
Vicarious Surgical (RBOT) is projected to burn $14 million in cash each quarter and will likely need to dilute existing shares or take on more debt due to its current cash balance.
"it's going to burn through about $14 million in cash each quarter with only 39 million in balance sheet cash as of the most recent report that means it will definitely need to dilute existing shares through convertible offerings and more debt"
Pending
Recursion Pharmaceuticals (RXRX) is expecting results for four of its Phase 2 pipeline trials within the next two quarters (Q3 and Q4 of 2024).
"four of which are in phase two and expecting results within the next two quarters"
Pending
Recursion Pharmaceuticals (RXRX) is expected to achieve 30% annual sales growth.
"strong intellectual property driving sales growth of 30% a year"
Pending
Certara (CERT) is expected to have revenue growth of 10% in 2024 and 2025.
"growth isn't quite as high as some of the other drug Discovery stocks with Revenue expected up 10% this year and next"
Pending
Schrodinger Inc.'s (SDRG) furthest drug indication is still in Phase One trials, meaning it will be years before any approvals are granted.
"Its furthest indication though is still in Phase One trials which means it's going to be years before any approvals"
Pending
The United States is projected to face a shortage of 124,000 doctors and over 78,000 nurses by the year 2030.
"we could be short as many as 124,000 doctors and more than 78,000 nurses by 2030"
Pending
The combined market size of healthcare robotics, medical devices, and drug discovery industries is projected to exceed $1.1 trillion.
"These three Industries alone will grow to over $1.1 trillion on current forecast"
Pending
The global healthcare robotics market is projected to grow 17% annually, reaching $76 billion by 2030.
"the global Healthcare robotics Market is already valued at nearly 26 billion dollar and projected to grow 17% annually to 76 billion by 2030"
Pending
The medical devices market is expected to grow from $542 billion to $886 billion by 2032.
"industry already at $542 billion and expected to grow to 886 billion by 2032"
Pending
The drug discovery market, currently at $65 billion, is projected to grow by 9% annually to exceed $133 billion by 2032.
"the drug Discovery Market at $65 billion is set to grow by 9% annually to over 133 billion by 2032"
Pending